Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01)

Chuanhua Zhao; Jun Zhao; Yigui Chen; Bo Liu; Yangfeng Du; Chenglin Li; Jingdong Zhang; Mudan Yang; Ying Liu; Yuxian Bai; Suyi Li; Ruixing Zhang; Fangling Ning; Yanping Liu; Kai Zou; Qi Zhang; Yijiao Xie; Yuping An; Jianming Xu

doi:10.1002/cac2.70080

Cancer Communications ›› 2025, Vol. 45 ›› Issue (12) :1755 -1759. DOI: 10.1002/cac2.70080

LETTER TO THE JOURNAL

Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01)

Author information +

¹. Senior Department of Oncology, Chinese PLA General Hospital, Beijing, P. R. China

². Department of Oncology, Changzhi People's Hospital, Changzhi, Shanxi, P. R. China

³. Department of Medicine, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, P. R. China

⁴. Department of Medical Oncology, Cancer Hospital of Shandong First Medical University, Jinan, Shandong, P. R. China

⁵. Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, P. R. China

⁶. Department of Clinical Pharmacology, Linyi People's Hospital, Linyi, Shandong, P. R. China

⁷. Department of Gastroenterology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, P. R. China

⁸. Department of Special Medical Services, Shanxi Province Cancer Hospital, Taiyuan, Shanxi, P. R. China

⁹. Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China

¹⁰. Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China

¹¹. Department of Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, P. R. China

¹². Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China

¹³. Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, P. R. China

¹⁴. Clinical Development Division, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, Hebei, P. R. China

jmxu2003@163.com

Show less

History +

PDF

Cite this article

Download citation ▾

Chuanhua Zhao, Jun Zhao, Yigui Chen, Bo Liu, Yangfeng Du, Chenglin Li, Jingdong Zhang, Mudan Yang, Ying Liu, Yuxian Bai, Suyi Li, Ruixing Zhang, Fangling Ning, Yanping Liu, Kai Zou, Qi Zhang, Yijiao Xie, Yuping An, Jianming Xu. Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01). Cancer Communications, 2025, 45(12): 1755-1759 DOI:10.1002/cac2.70080

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

[2]	Zeng H, Zheng R, Sun K, Zhou M, Wang S, Li L, et al. Cancer survival statistics in China 2019-2021: a multicenter, population-based study. J Natl Cancer Cent. 2024;4(3):203-13.

[3]	Fu R, Sun K, Wang X, Liu B, Wang T, Morze J, et al. Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study. The Lancet Regional Health – Western Pacific. 2023;37.

[4]	Huang D, Li ZS, Fan XS, Wu HM, Liu JP, Sun WY, et al. [HER2 status in gastric adenocarcinoma of Chinese: a multicenter study of 40 842 patients]. Article in Chinese. Zhonghua Bing Li Xue Za Zhi. 2018;47(11):822-6.

[5]

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.

[6]

Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197-208.

[7]	Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025.

[8]	Meric-Bernstam F, Hamilton EP, Beeram M, Hanna DL, El-Khoueiry AB, Kang Y-K, et al. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study. J Clin Oncol. 2021;39(3_suppl):164-.

[9]	Wei H, Cai H, Jin Y, Wang P, Zhang Q, Lin Y, et al. Structural basis of a novel heterodimeric Fc for bispecific antibody production. Oncotarget. 2017;8(31):51037-49.

[10]	Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. Cancer Cell. 2016;29(1):117-29.